EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
Summary
EyePoint experienced a severe stock crash after its late-stage clinical trial for a wet AMD treatment failed to meet its main goal. Following the unsuccessful study, the company announced it will reduce its workforce by more than half.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.